Autoimmune Complications Associated with Lemtrada Solved Using Anti-CD20 Therapies, Case Studies Suggest

Autoimmune Complications Associated with Lemtrada Solved Using Anti-CD20 Therapies, Case Studies Suggest

Publication date: Aug 07, 2019

This post was originally published on this site Relapsing-remitting multiple sclerosis (RRMS) patients treated with Lemtrada (alemtuzumab) may develop additional (secondary) autoimmune reactions. Anti-CD20 therapies, including rituximab or Ocrevus (ocrelizumab), are a potential treatment for Lemtrada-associated autoimmune complications in patients who fail to respond to other conventional immunotherapies, according to a case report about two women in Australia. The team considered that the autoimmune reactions in both RRMS patients were caused by an abnormal proliferation of B-cells as a result of Lemtrada treatment. Based on the results, the team suggested that -B-cell depletion therapy should be considered early in the treatment course of patients presenting with severe. ..autoimmune complications of alemtuzumab [Lemtrada],” and that -clinicians should remain vigilant when caring for patients undergoing alemtuzumab treatment,” they wrote. While both patients failed to respond to treatment with conventional immunotherapies, anti-CD20 therapies resulted in remission of secondary autoimmune diseases. Overall, the findings support the use of -anti-CD20 therapy as a potential treatment option in patients with autoimmune complications of alemtuzumab that are postulated to arise as a result of B-cell hyperpopulation,” the team concluded.

Concepts Keywords
Alemtuzumab Magnetic resonance imaging
Antibody Multiple sclerosis
Asymptomatic CD20
Australia Rituximab
Autoimmune Sanofi
Autoimmune Disease Alemtuzumab
Autoimmune Diseases Immunology
Autoimmune Response Genentech
B Cell Monoclonal antibodies
B Cells RTT
Bleeding Clinical medicine
Brain Medicine
CD20 Medical specialties
Clotting Factor Immunotherapy
Coagulation Immunotherapies
Corticosteroid Thrombocytopenia
Corticosteroids MS
Encephalitis Patient seizures
Epileptic Secondary immune diseases
Europe Autoimmune encephalitis
Factor VIII Autoimmune hypothyroidism
Fingolimod
Genentech
Genzyme
Gilenya
Hemophilia
Hormones
Humanized Monoclonal Antibody
Hypothyroidism
Immune Cells
Immune Reaction
Immunotherapies
Immunotherapy
Inflammation
Intubation
Joint Pain
Magnetic Resonance Imaging
Monoclonal Antibody
Multiple Sclerosis
Neurological
Novartis
Pharmacovigilance
Platelet
Prednisolone
Remission
Rituximab
Sanofi
Seizures
Thrombocytopenia
Thyroid Gland

Semantics

Type Source Name
disease MESH inflammation
disease DOID thrombocytopenia
disease MESH thrombocytopenia
disease DOID hypothyroidism
disease MESH hypothyroidism
drug DRUGBANK Rituximab
disease MESH bleeding
drug DRUGBANK Prednisolone
disease MESH hemophilia
drug DRUGBANK Beroctocog alfa
drug DRUGBANK Fingolimod
disease DOID autoimmune disease
disease MESH autoimmune disease
gene UNIPROT MAGEE1
disease MESH immune diseases
disease MESH Multiple Sclerosis
disease DOID Multiple Sclerosis
disease MESH disease progression
gene UNIPROT CD52
drug DRUGBANK Ocrelizumab
drug DRUGBANK Alemtuzumab
disease DOID Relapsing-remitting multiple sclerosis
disease MESH Relapsing-remitting multiple sclerosis
gene UNIPROT SLC35G1
gene UNIPROT DESI1
gene UNIPROT MS4A1
disease MESH Complications
drug DRUGBANK Nonoxynol-9
disease MESH autoimmune encephalitis
disease MESH seizures
disease MESH autoimmune response
disease DOID encephalitis
disease MESH encephalitis

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *